Methods and apparatus for magnetic separation of cells
| Title: | Methods and apparatus for magnetic separation of cells |
|---|---|
| Patent Number: | 8,071,395 |
| Publication Date: | December 06, 2011 |
| Appl. No: | 12/333213 |
| Application Filed: | December 11, 2008 |
| Abstract: | Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput. |
| Inventors: | Davis, Ronald W. (Palo Alto, CA, US); Jeffrey, Stefanie S. (Los Altos Hills, CA, US); Mindrinos, Michael N. (Menlo Park, CA, US); Pease, R. Fabian (Stanford, CA, US); Powell, Ashley Ann (Mountain View, CA, US); Hajhossein Talasaz, AmirAli (Los Altos, CA, US) |
| Assignees: | The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA, US) |
| Claim: | 1. A method for capturing and isolating cells comprising: (a) mixing a sample comprising rare target cells and contaminant cells with magnetically responsive particles having an affinity to the rare target cells to produce a sample solution having magnetically responsive particles bound to rare target cells; (b) contacting a magnetic member having a non-adherent sleeve with the sample solution; (c) producing a continuous relative motion between the magnetic member and the sample solution while the magnetic member produces a magnetic field across the non-adherent sleeve, such that the magnetically responsive particles bound to rare target cells are selectively captured onto the non-adherent sleeve and wherein the continuous relative motion is applied in concentric circles such that a majority of the sample solution has access to the magnetic member; (d) contacting the magnetic member having the captured rare target cells with a recovery solution; (e) substantially removing the magnetic field produced by the member across the non-adherent sleeve whereby the magnetically responsive particles bound to rare target cells are released into the recovery fluid. |
| Claim: | 2. The method of claim 1 wherein the non-adherent sleeve comprises a sleeve over the magnetic member, and step (e) of substantially removing magnetic field across the non-adherent sleeve comprises removing the magnetic member from at least a portion of the sleeve. |
| Claim: | 3. The method of claim 1 wherein the magnetic member comprises an electromagnet, and step (e) of substantially removing the magnetic field across the non-adherent sleeve comprises de-magnetizing the electromagnet. |
| Claim: | 4. The method of claim 1 wherein the magnetic member is held stationary in a fluid flow channel and the continuous relative motion between the magnetic member and the sample solution is produced by flowing the sample solution past the magnetic member. |
| Claim: | 5. The method of claim 1 where the continuous relative motion between the magnetic member and the sample solution produces a velocity in the non-turbulent flow regime. |
| Claim: | 6. The method of claim 1 wherein the continuous relative motion between the magnetic member and the sample solution has a Reynolds number of 0.1 to 100. |
| Claim: | 7. The method of claim 1 wherein the continuous relative motion between the magnetic member and the sample solution has velocity of 0.1 mm/sec to 1 mm/sec. |
| Claim: | 8. The method of claim 1 wherein the magnetic member has a surface field strength of 0.2 Tesla to 1 Tesla. |
| Claim: | 9. The method of claim 1 wherein the magnetic member has a surface field strength of 0.2 Tesla to 1 Tesla and the continuous relative motion between the magnetic member and the sample solution has velocity of 0.1 mm/sec to 1 mm/sec. |
| Claim: | 10. The method of claim 1 wherein the non-adherent sleeve comprises a polymer selected from the group consisting of vinyl, chlorofluorocarbon polymers and silicone. |
| Claim: | 11. The method of claim 1 wherein the non-adherent sleeve comprises polyvinyl chloride (PVC). |
| Claim: | 12. The method of claim 1 further comprising contacting the magnetic member, having captured rare target cells, with a wash fluid after step (c). |
| Claim: | 13. A method for capture and isolation of intact, rare target cells in a sample having a mixed cell population of target cells and contaminant cells, wherein the target cells are labeled with magnetically responsive material to form labeled target cells, comprising: (a) labeling the sample with a label specific for target cells, said label being magnetically responsive, to form a labeled sample; (b) contacting the labeled sample with a member extending into the sample and comprising a strong magnet covered by a nonmagnetic, nonadherent sleeve; (c) sweeping the member in a continuous motion through the sample to cause cells to attach to the sleeve wherein the sweeping is orbital; (d) washing the sleeve with cells attached to remove unlabeled cells into a cell free solution; (e) separating the magnet from the sleeve, whereby labeled cells are removed from the sleeve; and (f) collecting labeled cells to form a composition comprising beads and labeled cells. |
| Claim: | 14. The method of claim 13 further comprising the step of isolating a single labeled cell from the beads. |
| Claim: | 15. The method of claim 13 where the label is an antibody against an cell surface marker selected from the group consisting of HLA, EpCAM, CD44, and CD96. |
| Claim: | 16. The method of claim 13 where the sample is human peripheral blood. |
| Claim: | 17. The method of claim 13 where the target cells are CTCs. |
| Claim: | 18. The method of claim 13 where the strong magnet is a rare earth magnet having an axial dipole whereby magnetic particles are concentrated at one elongated end of the magnet. |
| Claim: | 19. The method of claim 13 wherein the nonadherent sleeve is a polymer. |
| Claim: | 20. The method of claim 13 wherein the polymer is a polymer selected from the group consisting of polyvinyl chloride, chlorofluorocarbon polymers or silicone. |
| Claim: | 21. The method of claim 13 further comprising the step of applying a magnetic field opposite the sleeve after the magnet has been removed to assist in removing labeled cells from the sleeve. |
| Claim: | 22. The method of claim 13 further comprising multiple washing steps as recited in step (d). |
| Claim: | 23. The method of claim 13 further comprising the step of extracting intact genetic material from isolated target cells. |
| Claim: | 24. The method of claim 13 further comprising the step of testing for expression of certain genes in extracted genetic material. |
| Claim: | 25. The method of claim 24 wherein the genes are selected from the group consisting of GAPDH Beta Actin, Big ribosome protein (RPLPO), CRYAB, EGFR, FOXA1, CD44, ESR1 (ER) PGR (PR), and mutated forms of Myc, Ras, BRCA1, BRCA2, APC, and p53. |
| Claim: | 26. The method of claim 24 comprising the testing for the expression of vimentin, where increased expression of vimentin indicates a mesenchymal CTC. |
| Claim: | 27. The method of claim 1 wherein the magnetic member produces a magnetic field across a non-adherent sleeve which is a polymer through which the magnetic field is transmitted. |
| Claim: | 28. A method for capturing and isolating cells comprising: (a) mixing a sample comprising rare target cells and contaminant cells with magnetically responsive particles having an affinity to the rare target cells to produce a sample solution having magnetically responsive particles bound to rare target cells; (b) contacting a magnetic member having a non-adherent sleeve with the sample solution; (c) producing a continuous relative motion between the magnetic member and the sample solution while the magnetic member produces a magnetic field across the non-adherent sleeve, such that the magnetically responsive particles bound to rare target cells are selectively captured onto the non-adherent sleeve and wherein said continuous relative motion is orbital; (d) contacting the magnetic member having the captured rare target cells with a recovery solution; (e) substantially removing the magnetic field produced by the member across the non-adherent sleeve whereby the magnetically responsive particles bound to rare target cells are released into the recovery fluid. |
| Claim: | 29. The method of claim 28 wherein the non-adherent sleeve comprises a sleeve over the magnetic member, and step (e) of substantially removing magnetic field across the non-adherent sleeve comprises removing the magnetic member from at least a portion of the sleeve. |
| Claim: | 30. The method of claim 28 wherein the magnetic member comprises an electromagnet, and step (e) of substantially removing the magnetic field across the non-adherent sleeve comprises de-magnetizing the electromagnet. |
| Claim: | 31. The method of claim 28 wherein the magnetic member is held stationary in a fluid flow channel and the continuous relative motion between the magnetic member and the sample solution is produced by flowing the sample solution past the magnetic member. |
| Claim: | 32. The method of claim 28 where the continuous relative motion between the magnetic member and the sample solution produces a velocity in the non-turbulent flow regime. |
| Claim: | 33. The method of claim 28 wherein the continuous relative motion between the magnetic member and the sample solution has a Reynolds number of 0.1 to 100. |
| Claim: | 34. The method of claim 28 wherein the continuous relative motion between the magnetic member and the sample solution has velocity of 0.1 mm/sec to 1 mm/sec. |
| Claim: | 35. The method of claim 28 wherein the magnetic member has a surface field strength of 0.2 Tesla to 1 Tesla. |
| Claim: | 36. The method of claim 28 wherein the magnetic member has a surface field strength of 0.2 Tesla to 1 Tesla and the continuous relative motion between the magnetic member and the sample solution has velocity of 0.1 mm/sec to 1 mm/sec. |
| Claim: | 37. The method of claim 28 wherein the continuous relative motion is applied such that a majority of the sample solution has access to the magnetic member. |
| Claim: | 38. The method of claim 28 wherein the non-adherent sleeve comprises a polymer selected from the group consisting of vinyl, chlorofluorocarbon polymers and silicone. |
| Claim: | 39. The method of claim 28 wherein the non-adherent sleeve comprises polyvinyl chloride (PVC). |
| Claim: | 40. The method of claim 28 further comprising contacting the magnetic member, having captured rare target cells, with a wash fluid after step (c). |
| Claim: | 41. The method of claim 28 wherein the magnetic member produces a magnetic field across a non-adherent sleeve which is a polymer through which the magnetic field is transmitted. |
| Current U.S. Class: | 436/524 |
| Patent References Cited: | 2517325 August 1950 Lamb 3970518 July 1976 Giaever 5186827 February 1993 Liberti et al. 5200084 April 1993 Liberti et al. 5215926 June 1993 Etchells, III et al. 5536475 July 1996 Moubayed et al. 5567326 October 1996 Ekenberg et al. 5597531 January 1997 Liberti et al. 5622831 April 1997 Liberti et al. 5646001 July 1997 Terstappen et al. 5837144 November 1998 Bienhaus et al. 5876593 March 1999 Liberti et al. 5942124 August 1999 Tuunanen 5972721 October 1999 Bruno et al. 6040192 March 2000 Tuunanen 6065605 May 2000 Korpela et al. 6184043 February 2001 Fodstad et al. 6190870 February 2001 Schmitz et al. 6207463 March 2001 Tuunanen 6365362 April 2002 Terstappen et al. 6403038 June 2002 Hermann 6409925 June 2002 Bombinsky et al. 6448092 September 2002 Tuunanen 6468432 October 2002 Miltenyi et al. 6468810 October 2002 Korpela 6500343 December 2002 Siddiqi 6551843 April 2003 Rao et al. 6596162 July 2003 Tuunanen 6649419 November 2003 Anderson 6730217 May 2004 Schaaf et al. D502450 March 2005 Rundt et al. 6890426 May 2005 Terstappen et al. 7056657 June 2006 Terstappen et al. 7125964 October 2006 Luxembourg et al. 7138269 November 2006 Blankenstein 7282350 October 2007 Rao et al. 7332288 February 2008 Terstappen et al. 2002/0172987 November 2002 Terstappen et al. 2002/0183692 December 2002 Callister 2003/0044832 March 2003 Blankenstein 2004/0072269 April 2004 Rao et al. 2006/0134599 June 2006 Toner et al. 2006/0194192 August 2006 Rao et al. 2006/0257847 November 2006 Scholtens et al. 2006/0266130 November 2006 Zobel et al. 2007/0018764 January 2007 Martinez Garcia et al. 2007/0026417 February 2007 Fuchs et al. 2007/0037173 February 2007 Allard et al. 2007/0154960 July 2007 Connelly et al. 2007/0251885 November 2007 Korpela et al. 2008/0305473 December 2008 Chowdary et al. 0593480 August 1991 0593480 April 1994 1058851 February 1999 1058851 December 2000 1425294 August 2002 1425294 June 2004 8705536 September 1987 96/09550 March 1996 99040444 August 1999 0206790 January 2002 03069421 August 2003 2004076643 September 2004 2005/028663 March 2005 2006/041453 April 2006 2006042005 April 2006 2006054991 May 2006 2006102233 September 2006 2006104474 October 2006 2006105319 October 2006 2007053142 May 2007 2007053245 May 2007 2007063174 June 2007 2007086047 August 2007 2007106523 September 2007 2008048027 April 2008 |
| Other References: | Allard, Jeffrey W., et al., “Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases,” Clinical Cancer Research, Oct. 15, 2004, vol. 10, 6897-6904. cited by other Patrawalla, Lubna, et al., “Side Population Is Enriched in Tumorigenic, Stem-Like Cancer Cells, whereas ABCG2+ and ABCG2- Cancer Cells Are Similarly Tumorigenic,” Cancer Research, Jul. 15, 2005, vol. 65, No. 14, 6207-6219. cited by other Tong, Xiadong, et al., “Application of Immunomagnetic Cell Enrichment in Combination with RT-PCR for the Detection of Rare Circulating Head and Neck Tumor Cells in Human Peripheral Blood,” Clinical Cytometry, 2007, 72B:310-323. cited by other Powell, Ashley A., et al., “MagSweeper: An Automated System for High Specificity Capture of Live Circulating Tumor Cells,” Poster, Presented at San Antonio Breast Cancer Symposium, Dec. 12, 2007. cited by other Talasaz, AH, et al., “Development of a New Device for High Throughput Isolation of Live Circulating Tumor Cells,” Poster, Presented at San Antonio Breast Cancer Symposium, Dec. 16, 2006. cited by other 3815.53-1PCT International Search Report and Written Opinion,Feb. 4, 2009. cited by other Liberti, et al., “Optimization of ferrofluids and protocols for the enrichment of breast tumor cells in blood”, Journal of Magnetism and Magnetic Materials, 225 (2001) 301-307. cited by other Riethdorf, et al., “Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the cellsearch system”, Clin Cancer Res 2007;13(3) Feb. 1, 2007, pp. 920-928. cited by other European Search Report, Application No. 08859615.0, Apr. 7, 2011. cited by other |
| Primary Examiner: | Yang, N |
| Attorney, Agent or Firm: | Aston, David J. Peters Verny, LLP |
| Accession Number: | edspgr.08071395 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|